- Home
- Natural Killer Nk Cell Therapeutics Market
Global Natural Killer (Nk) Cell Therapeutics Market - Industry Trends And Forecast To 2029
- Published Date: September, 2022 | Report ID: CLS-503 | No of pages: 286 | Format:
Global natural killer (NK) cell therapeutics market is projected to register a CAGR of 40.9% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021 and the forecast period is 2022 to 2029
Market Segmentation:
Global Natural Killer (NK) Cell Therapeutics Market, By Therapeutics (NK Cell Therapies, NK Cell Directed Antibodies), Approaches (Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), Bispecific Antibodies), Application (Cancer, Acute Infectious Diseases, Gastrointestinal Diseases, Others), End User (Research & Academic Institutes, Hospitals, Specialty Clinics), Distribution Channel (Hospital Pharmacies, Direct Tender, Others), Country (U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg, Rest of Europe, Japan, China, Australia, South Korea, India, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt and rest of Middle East and Africa) Industry Trends and Forecast to 2029
Some of the major factors contributing to the growth of the global natural killer (NK) cell therapeutics market are:
Increase in usage of natural killer (NK) cells for the treatment of cancer and infectious diseases
Rise in awareness about immunotherapies
Adoption of natural killer (NK) cell therapy in emerging markets
Market Players:
The key market players for global natural killer (NK) cell therapeutics market are listed below:
Merck KGaA
Bristol-Myers Squibb Company
Glycostem
Kiadis Pharma
Cytovia Therapeutics
Nkarta, Inc.
Nektar
ImmunityBio, Inc.
Brink Biologics, Inc.
Biohaven Pharmaceuticals
Fate Therapeutics
EMERcell
Phio Pharmaceuticals
PersonGen BioTherapeutics
Innate Pharma, Inc.
INmuneBIO
Gamida Cell
Acepodia Inc.
Affimed GmbH
Multimmune GmbH
iCell Gene Therapeutics
Takeda Pharmaceutical Company Limited
Regeneron Pharmaceuticals Inc.
TABLE OF CONTENT
TABLE OF CONTENTS 1 INTRODUCTION 31 1.1 OBJECTIVES OF THE STUDY 31 1.2 MARKET DEFINITION 31 1.3 OVERVIEW OF GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET 31 1.4 LIMITATIONS 33 1.5 MARKETS COVERED 34 2 MARKET SEGMENTATION 36 2.1 MARKETS COVERED 36 2.2 GEOGRAPHICAL SCOPE 37 2.3 YEARS CONSIDERED FOR THE STUDY 38 2.4 CURRENCY AND PRICING 38 2.5 DBMR TRIPOD DATA VALIDATION MODEL 39 2.6 MULTIVARIATE MODELLING 42 2.7 THERAPEUTICS LIFELINE CURVE 42 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 43 2.9 DBMR MARKET POSITION GRID 44 2.10 SECONDARY SOURCES 46 2.11 ASSUMPTIONS 46 3 EXECUTIVE SUMMARY 47 3.1 EPIDEMIOLOGY 53 3.2 PESTEL ANALYSIS 54 3.3 PORTERS FIVE FORCES MODEL 55 3.4 INDUSTRIAL INSIGHTS: 56 3.5 PIPELINE ANALYSIS 58 4 GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET: REGULATIONS 59 5 MARKET OVERVIEW 61 5.1 DRIVERS 63 5.1.1 INCREASE IN USAGE OF NATURAL KILLER (NK) CELLS FOR THE TREATMENT OF CANCER AND INFECTIOUS DISEASES 63 5.1.2 INCREASE IN PATIENT POPULATION WITH CHRONIC DISEASES 63 5.1.3 RISE IN AWARENESS ABOUT IMMUNOTHERAPIES 64 5.1.4 ADOPTION OF NATURAL KILLER (NK) CELL THERAPY IN EMERGING MARKETS 64 5.2 RESTRAINTS 65 5.2.1 LACK OF SPECIFICITY AND POOR IN-VIVO SURVIVAL OF THE CELLS 65 5.2.2 ADVERSE SIDE EFFECTS OF THERAPIES 65 5.2.3 HIGH COST ASSOCIATED WITH THE THERAPIES 66 5.3 OPPORTUNITIES 67 5.3.1 ADVANCEMENT IN NATURAL KILLER (NK) CELL THERAPIES 67 5.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS 67 5.3.3 RISE IN EXPENDITURE IN HEALTHCARE SECTOR 68 5.4 CHALLENGES 68 5.4.1 LONG APPROVAL TIME FOR IMMUNOTHERAPIES 68 5.4.2 LACK OF SPECIFIC TREATMENT BY NATURAL KILLER (NK) CELLS 69 5.4.3 AVAILABILITY OF ALTERNATIVES FOR TUMOR TREATMENT 69 6 GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY THERAPEUTICS 71 6.1 OVERVIEW 72 6.2 NK CELL THERAPIES 75 6.3 NK CELL DIRECTED ANTIBODIES 75 7 GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPROACHES 77 7.1 OVERVIEW 78 7.2 ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC) 81 7.3 BISPECIFIC ANTIBODIES 82 8 GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY APPLICATION 83 8.1 OVERVIEW 84 8.2 CANCER 87 8.2.1 SOLID TUMORS 88 8.2.2 HEMATOLOGIC MALIGNANCIES 88 8.2.2.1 MULTIPLE MYELOMA 89 8.2.2.2 ACUTE MYELOID LEUKEMIA (AML) 89 8.2.2.3 LYMPHOMA 89 8.2.2.4 OTHERS 89 8.2.3 OTHERS 89 8.3 IMMUNOPROLIFERATIVE DISORDERS 89 8.4 ACUTE INFECTIOUS DISEASES 90 8.5 GASTROINTESTINAL DISEASES 90 8.6 OTHERS 91 9 GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY END USER 93 9.1 OVERVIEW 94 9.2 HOSPITALS 97 9.3 SPECIALTY CLINICS 97 9.4 RESEARCH & ACADEMIC INSTITUTES 98 10 GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL 100 10.1 OVERVIEW 101 10.2 HOSPITAL PHARMACIES 104 10.3 DIRECT TENDER 104 10.4 OTHERS 105 11 GLOBAL NATURAL KILLER (NK) CELL THERAPEUTICS MARKET, BY REGION 106 11.1 OVERVIEW 107 11.2 NORTH AMERICA 112 11.2.1 U.S. 119 11.2.2 CANADA 122 11.2.3 MEXICO 125 11.3 EUROPE 128 11.3.1 GERMANY 135 11.3.2 FRANCE 137 11.3.3 ITALY 139 11.3.4 U.K. 141 11.3.5 SPAIN 143 11.3.6 NETHERLANDS 145 11.3.7 RUSSIA 147 11.3.8 SWITZERLAND 149 11.3.9 TURKEY 151 11.3.10 AUSTRIA 153 11.3.11 NORWAY 155 11.3.12 HUNGARY 157 11.3.13 LITHUANIA 159 11.3.14 IRELAND 161 11.3.15 POLAND 163 11.3.16 LUXEMBOURG 165 11.3.17 REST OF EUROPE 167 11.4 ASIA-PACIFIC 168 11.4.1 JAPAN 175 11.4.2 CHINA 177 11.4.3 AUSTRALIA 179 11.4.4 SOUTH KOREA 181 11.4.5 INDIA 183 11.4.6 SINGAPORE 185 11.4.7 MALAYSIA 187 11.4.8 THAILAND 189 11.4.9 INDONESIA 191 11.4.10 PHILIPPINES 193 11.4.11 VIETNAM 195 11.4.12 REST OF ASIA-PACIFIC 197 11.5 SOUTH AMERICA 198 11.5.1 BRAZIL 204 11.5.2 ARGENTINA 206 11.5.3 PERU 208 11.5.4 REST OF SOUTH AMERICA 210 11.6 MIDDLE EAST & AFRICA 211 11.6.1 SAUDI ARABIA 218 11.6.2 SOUTH AFRICA 220 11.6.3 U.A.E 222 11.6.4 ISRAEL 224 11.6.5 KUWAIT 226 11.6.6 EGYPT 228 11.6.7 REST OF MIDDLE EAST & AFRICA 230 12 GLOBAL NATURAL KILLER (NK) CELLS THERAPEUTICS MARKET, COMPANY LANDSCAPE 231 12.1 COMPANY SHARE ANALYSIS: GLOBAL 231 13 SWOT ANALYSIS 232 14 COMPANY PROFILE 233 14.1 MERCK KGAA 233 14.1.1 COMPANY SNAPSHOT 233 14.1.2 RECENT FINANCIALS 233 14.1.3 PRODUCT PORTFOLIO 234 14.1.4 RECENT DEVELOPMENTS 234 14.2 BRISTOL-MYERS SQUIBB COMPANY 236 14.2.1 COMPANY SNAPSHOT 236 14.2.2 RECENT FINANCIALS 236 14.2.3 PRODUCT PORTFOLIO 237 14.2.4 RECENT DEVELOPMENTS 237 14.3 GLYCOSTEM 239 14.3.1 COMPANY SNAPSHOT 239 14.3.2 PRODUCT PORTFOLIO 239 14.3.3 RECENT DEVELOPMENTS 239 14.4 INNATE PHARMA, INC. 241 14.4.1 COMPANY SNAPSHOT 241 14.4.2 REVENUE ANALYSIS 241 14.4.3 PRODUCT PORTFOLIO 242 14.4.4 RECENT DEVELOPMENTS 242 14.5 REGENERON PHARMACEUTICALS INC. 244 14.5.1 COMPANY SNAPSHOT 244 14.5.2 RECENT FINANCIALS 244 14.5.3 PRODUCT PORTFOLIO 245 14.5.4 RECENT DEVELOPMENTS 245 14.6 TAKEDA PHARMACEUTICAL COMPANY LIMITED 246 14.6.1 COMPANY SNAPSHOT 246 14.6.2 RECENT FINANCIALS 246 14.6.3 PRODUCT PORTFOLIO 247 14.6.4 RECENT DEVELOPMENTS 247 14.7 INMUNEBIO 248 14.7.1 COMPANY SNAPSHOT 248 14.7.2 REVENUE ANALYSIS 248 14.7.3 PRODUCT PORTFOLIO 249 14.7.4 RECENT DEVELOPMENTS 249 14.8 KIADIS PHARMA 251 14.8.1 COMPANY SNAPSHOT 251 14.8.2 REVENUE ANALYSIS 251 14.8.3 PRODUCT PORTFOLIO 252 14.8.4 RECENT DEVELOPMENTS 252 14.9 ACEPODIA INC. 254 14.9.1 COMPANY SNAPSHOT 254 14.9.2 PRODUCT PORTFOLIO 254 14.9.3 RECENT DEVELOPMENTS 254 14.10 AFFIMED GMBH 256 14.10.1 COMPANY SNAPSHOT 256 14.10.2 RECENT FINANCIALS 256 14.10.3 PRODUCT PORTFOLIO 257 14.10.4 RECENT DEVELOPMENTS 257 14.11 BIOHAVEN PHARMACEUTICALS 259 14.11.1 COMPANY SNAPSHOT 259 14.11.2 REVENUE ANALYSIS 259 14.11.3 PRODUCT PORTFOLIO 260 14.11.4 RECENT DEVELOPMENTS 260 14.12 BRINK BIOLOGICS, INC. 261 14.12.1 COMPANY SNAPSHOT 261 14.12.2 PRODUCT PORTFOLIO 261 14.12.3 RECENT DEVELOPMENT 261 14.13 CYTOVIA THERAPEUTICS 262 14.13.1 COMPANY SNAPSHOT 262 14.13.2 PRODUCT PORTFOLIO 262 14.13.3 RECENT DEVELOPMENTS 262 14.14 EMERCELL 264 14.14.1 COMPANY SNAPSHOT 264 14.14.2 PRODUCT PORTFOLIO 264 14.14.3 RECENT DEVELOPMENTS 264 14.15 FATE THERAPEUTICS 265 14.15.1 COMPANY SNAPSHOT 265 14.15.2 REVENUE ANALYSIS 265 14.15.3 PRODUCT PORTFOLIO 266 14.15.4 RECENT DEVELOPMENTS 266 14.16 GAMIDA CELL 268 14.16.1 COMPANY SNAPSHOT 268 14.16.2 PRODUCT PORTFOLIO 268 14.16.3 RECENT DEVELOPMENTS 269 14.17 ICELL GENE THERAPEUTICS 270 14.17.1 COMPANY SNAPSHOT 270 14.17.2 PRODUCT PORTFOLIO 270 14.17.3 RECENT DEVELOPMENT 270 14.18 IMMUNITYBIO, INC. 271 14.18.1 COMPANY SNAPSHOT 271 14.18.2 REVENUE ANALYSIS 271 14.18.3 PRODUCT PORTFOLIO 272 14.18.4 RECENT DEVELOPMENTS 272 14.19 MULTIMMUNE GMBH 273 14.19.1 COMPANY SNAPSHOT 273 14.19.2 PRODUCT PORTFOLIO 273 14.19.3 RECENT DEVELOPMENTS 273 14.20 NEKTAR 274 14.20.1 COMPANY SNAPSHOT 274 14.20.2 REVENUE ANALYSIS 274 14.20.3 PRODUCT PORTFOLIO 275 14.20.4 RECENT DEVELOPMENTS 275 14.21 NKARTA, INC. 276 14.21.1 COMPANY SNAPSHOT 276 14.21.2 PRODUCT PORTFOLIO 276 14.21.3 RECENT DEVELOPMENTS 276 14.22 PERSONGEN BIOTHERAPEUTICS 278 14.22.1 COMPANY SNAPSHOT 278 14.22.2 PRODUCT PORTFOLIO 278 14.22.3 RECENT DEVELOPMENTS 278 14.23 PHIO PHARMACEUTICALS 280 14.23.1 COMPANY SNAPSHOT 280 14.23.2 PRODUCT PORTFOLIO 280 14.23.3 RECENT DEVELOPMENTS 280 15 QUESTIONNAIRE 282 16 RELATED REPORTS 286Segmentation
Short Description Global Natural Killer (NK) Cell Therapeutics Market, By Therapeutics (NK Cell Therapies, NK Cell Directed Antibodies), Approaches (Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), Bispecific Antibodies), Application (Cancer, Acute Infectious Diseases, Gastrointestinal Diseases, Others), End User (Research & Academic Institutes, Hospitals, Specialty Clinics), Distribution Channel (Hospital Pharmacies, Direct Tender, Others), Country (U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg, Rest of Europe, Japan, China, Australia, South Korea, India, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt and rest of Middle East and Africa) Industry Trends and Forecast to 2029 Market Definition: Natural killer (NK) cells are the large granular lymphocytes which have the ability to quickly respond to a pathological challenge. Natural killer cells are the important component of innate immune system and play an important role in generating immune response against the malignancies and infectious diseases caused by viral pathogens. Natural killer (NK) cells have been recognized to induce direct killing of targeted cells involving cancer cells. These have the ability to recognize the multitude of infected cells without being dependent on a single antigen expressing cells. NK cells secrete cytokines and chemokines which recruit other immune cells such as T cells and B cells which enhances the immune response against the tumor cells. As Natural killer (NK) cells do not express T cell receptors, they induce low risk of graft-versus-host disease. The effectiveness of NK cells therapies can be also be enhanced by genetically modified the NK cells so as to obtain highly specific and persistent cell lines. NK cell therapies can also be used with mono-clonal antibodies and T-cell therapies which again enhances its anti-tumor activity. Increase in usage of natural killer cells for the treatment of cancer and infectious disease is a key factor responsible for market growth. Along with this rise in patients population with chronic disease and rise in the awareness about immunotherapies boosting the market growth. Market Segmentation: Natural killer (NK) cell therapeutics market is categorized into four notable segments which are based on therapeutics, approaches, application, end user, and distribution channel. On the basis of therapeutics, the natural killer (NK) cell therapeutics market is segmented into NK cell therapies and NK cell directed antibodies On the basis of approaches, the natural killer (NK) cell therapeutics market is segmented into antibody-dependent cell-mediated cytotoxicity (ADCC) and bispecific antibodies. On the basis of application, the natural killer (NK) cell therapeutics market is segmented into cancer, acute infectious diseases, gastrointestinal diseases and others. Cancer is further sub-segmented into solid tumors, hematologic malignancies and others. Hematologic malignancies are further sub-segmented into multiple myeloma, acute myeloid leukemia (AML), lymphoma and others. On the basis of end user, the natural killer (NK) cell therapeutics market is segmented into hospitals, specialty clinics, and research & academic institutes On the basis of distribution channel, the natural killer (NK) cell therapeutics market is segmented into hospital pharmacies, direct tender, others. Market Players The key market players for natural killer (NK) cell therapeutics market are listed below: Merck KGaA Bristol-Myers Squibb Company Glycostem Kiadis Pharma Cytovia Therapeutics Nkarta, Inc. Nektar ImmunityBio, Inc. Brink Biologics, Inc. Biohaven Pharmaceuticals Fate Therapeutics EMERcell Phio Pharmaceuticals PersonGen BioTherapeutics Innate Pharma, Inc. INmuneBIO Gamida Cell Acepodia Inc. Affimed GmbH Multimmune GmbH iCell Gene Therapeutics Takeda Pharmaceutical Company Limited Regeneron Pharmaceuticals Inc.Methodology
Why Choose Us
24 * 7 Access to Analyst :
Get your pre and post sales queries resolved by our Subject matter experts.
Customization :
We will assist you to customize the report to fit your research needs.
Assured Quality :
Our prime focus is to provide qualitative and accurate data.
Free sample report :
Feel free to order a sample report before purchase.
Security :
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.